Cytomegalovirus

oPatientPlus articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.

Cytomegalovirus (CMV) is a member of the herpesvirus family. Infection is worldwide and usually asymptomatic. CMV may cause a mononucleosis infection in healthy individuals but can cause severe illness in congenital infection and in an immunocompromised host.

The most common disease manifestation is gastrointestinal disease. CMV pneumonia is the most serious complication, but has become less common with prevention strategies for at-risk patients. Rare manifestations include retinitis and encephalitis. CMV also has an immunosuppressive effect, which can lead to an increased susceptibility to invasive bacterial and fungal disease as well as graft-versus-host disease (GVHD).[1]

  • After initial infection, human CMV remains in a persistent state within the host. Immunity against the virus controls replication, although intermittent viral shedding can still take place in the immunocompetent person.
  • Complications are therefore mainly seen if the immune system is immature, or is suppressed by drug treatment or co-infection with other pathogens.
  • Clinically significant CMV disease frequently develops in patients immunocompromised as a result of HIV, solid organ transplantation and bone-marrow transplantation.[2]
  • Primary CMV infection of the immunocompromised host may cause disease in almost every organ of the body - eg, pneumonia, hepatitis, encephalitis, colitis, uveitis, retinitis and neuropathy.
  • 50-80% of all adults are infected with CMV.
  • Infection may be passed via body fluids - eg, kissing, sexual intercourse, blood transfusion, or by tissue donation.
  • Most HIV-infected individuals are seropositive for CMV. HIV infection accelerates the development of CMV-dependent immunological abnormalities.[3]

NEW - log your activity

  • Notes Add notes to any clinical page and create a reflective diary
  • Track Automatically track and log every page you have viewed
  • Print Print and export a summary to use in your appraisal
Click to find out more »

CMV is usually an asymptomatic infection. In immunocompetent individuals, symptomatic disease usually manifests as a mononucleosis syndrome.[2]

  • Infection is usually asymptomatic in infants and children.
  • In adolescence and early adulthood, primary infection is also usually asymptomatic but may cause a mild flu-like illness.
  • CMV may also produce a mononucleosis syndrome similar to Epstein-Barr virus (causing a febrile illness with splenomegaly, impaired liver function, and abnormal lymphocytes in the blood), but without characteristic pharyngitis and lymphadenopathy.
  • Complications of infection are uncommon in immunocompetent hosts, but include:
  • Hepatitis is commonly observed in patients with primary CMV infection and mononucleosis. LFTs may show mild transient increases in liver enzymes, but elevations in alkaline phosphatase and bilirubin are much less common. Prognosis is excellent in immunocompetent individuals.
  • CMV hepatitis may also cause granulomatous involvement but, again, usually with complete recovery.
  • Immunocompetent:
    • Pneumonia may occasionally occur with CMV mononucleosis.
    • Usually, pneumonia is found on the CXR but is of no clinical significance, and rapidly resolves with the disappearance of the primary infection.
  • Immunocompromised:
    • The most common clinical presentation is fever and shortness of breath, associated with an interstitial infiltrate on the CXR.
    • Pneumonia is particularly severe after marrow or solid organ transplant, and then has a high mortality.
    • The differential diagnosis in patients who are immunocompromised includes pneumocystis pneumonia, pulmonary haemorrhage, drug toxicity, lymphoma and other infections.
  • CMV is the most common congenitally acquired infection in infants.
  • Placental infection occurs more commonly during primary infection. Symptomatic congenital infection is more likely to occur in babies of women without pre-existing immunity to CMV.
  • CMV may be found in both cervical secretions and in breast milk.
  • Most children infected in utero appear healthy but may manifest late sequelae. Those children born with cytomegalic inclusion disease have a poor prognosis.
  • In about 10-20% of cases, follow-up shows neurological damage. Sensorineural hearing loss is the most frequent long-term consequence and in many cases does not become clinically apparent until later childhood.[5] 
  • Other sequelae that may be evident only after the neonatal period can include chorioretinitis, neurodevelopmental delay with mental or motor impairment, and microcephaly.[6]
  • Cytomegalic inclusion disease:
    • Presents with jaundice, splenomegaly, petechiae (thrombocytopenia), intrauterine growth restriction, microcephaly, and retinitis.
    • Complications include moderate to severe learning difficulties, neurological abnormalities, hearing loss.
    • CMV excretion is common in children with congenital infection, and this may represent a reservoir for infection of other children and daycare workers.

CMV is one of the most important pathogens that infect solid organ transplant recipients and is associated with increased morbidity and mortality.[8] Solid organ transplant recipients are particularly susceptible to CMV-related disease due to the immunosuppression necessary to prevent organ rejection. Patients receiving T-cell depleting therapies are at the highest risk.[9] The major risk factor for CMV pneumonia is a CMV-seronegative transplant recipient receiving a CMV-seropositive organ.

Because of the multiple human strains of CMV, seropositive organ recipients are at risk of re-infection with a different strain of virus. The clinical syndrome is then usually less severe than in primary infection and the onset of disease is often delayed to approximately 6-8 weeks post-transplantation.

Prevention of CMV infection

  • All organ donors and recipients should be screened for CMV status prior to, or at the time of, transplantation.
  • Where both donor and recipient are seronegative for CMV, leuko-depleted blood and blood products should be used to minimise the risk of primary infection. In this situation, no prophylaxis or monitoring is required.
  • CMV-seronegative recipients who receive a solid organ transplant from a donor who is seropositive should be offered prophylaxis against primary infection using oral valganciclovir, oral valaciclovir or intravenous ganciclovir. The same should apply where either the donor or recipient is seropositive if the patient is treated with T-cell depleting antibodies.
  • When the donor and recipient are both seropositive and the patient is not treated with T-cell depleting antibody therapy:
    • For renal transplant recipients: no prophylaxis is recommended.
    • For liver transplant recipients: no prophylaxis is recommended.
    • For lung transplant recipients: the recommended prophylactic strategy is oral valganciclovir or oral valaciclovir.
    • For heart transplant recipients: no prophylaxis is recommended.
  • Serial measurements of viral load and treatment with intravenous ganciclovir can be used when levels predictive of disease are reached.

Treatment

  • Patients with CMV disease should receive intravenous ganciclovir or oral valganciclovir until resolution of symptoms and for a minimum of 14 days. Foscarnet and cidofovir are second-line therapeutic options unless ganciclovir resistance has been demonstrated.
  • A reduction in immunosuppression should be considered if possible.
  • After treatment doses have been administered, an additional 1-3 months of appropriate prophylaxis should be considered to minimise the risk of recurrent infection.
  • The duration and efficacy of treatment should be determined using PCR monitoring of viral load.

CMV can cause very serious infection in HIV infection.

  • Retinitis:
    • Retinitis is the most common manifestation of CMV disease in patients who are HIV positive.
    • It presents with decreased visual acuity, floaters, and loss of visual fields on one side.
    • Ophthalmological examination shows yellow-white areas with perivascular exudates. Haemorrhage is present. Lesions may appear at the periphery of the fundus, but they progress centrally.
    • It begins as a unilateral disease, but in many cases it progresses to bilateral involvement. It may be accompanied by systemic CMV disease.
    • Ganciclovir has been used to treat retinitis, but it only slows the progression of the disease. The optimal treatment is using ganciclovir implants in the vitreous, accompanied by intravenous ganciclovir therapy.
    • Oral ganciclovir may be used for prophylaxis of CMV retinitis. It should not be used for treatment.
  • CMV pneumonia in patients who are HIV positive is uncommon. The reason for this is unknown.
  • Gastrointestinal tract:
    • In the upper gastrointestinal tract, CMV has been isolated from oesophageal, gastric and duodenal ulcers. Patients with oesophageal disease may present with painful dysphagia.
    • In the lower gastrointestinal tract, patients with CMV may present with diarrhoea due to colitis.
  • CMV may cause disease in the peripheral and central nervous system.

CMV can be detected by culture, serology, antigen assays, PCR, and cytopathology.[2] 

  • CMV antibody: IgM and IgG:[2] 
    • Recent CMV infection causes an increased IgM level and a four-fold increase in IgG.
    • False-positive CMV IgM results may be seen in patients with Epstein-Barr virus or human herpesvirus 6 infections, and in patients with increased levels of rheumatoid factor.
  • Antigen detection: antigenaemia has been used to predict CMV pneumonia in patients who have received transplants, and therefore used as an indication to start ganciclovir therapy.
  • PCR: has been used to detect CMV in blood and tissue samples. The test is very sensitive. It is positive before the antigenaemia test in patients with viraemia who have received transplants.
  • Shell vial assay: reduces the time required for tissue culture to 24-48 hours, and therefore allows much quicker and more effective initiation of treatment.
  • CXR: findings consistent with pneumonia and positive CMV serology is a common method for diagnosis.
  • CT scan is more sensitive for the identification of lung infiltrates.
  • Biopsy: the histological hallmark of CMV infection is the finding of intranuclear inclusions consistent with herpesvirus infection.

The drug of choice for treatment of CMV disease is intravenous ganciclovir, although valganciclovir may be used for CMV treatment in selected cases.[2] 

  • Ganciclovir:
    • Ganciclovir is related to aciclovir but it is more active against cytomegalovirus. It is also much more toxic than aciclovir.
    • Oral ganciclovir provides much lower serum levels than intravenous, and so oral ganciclovir is mainly restricted to use as prophylaxis for CMV disease.
    • Intravenous ganciclovir is used for the initial treatment of CMV retinitis. Slow-release ocular implants containing ganciclovir may be inserted surgically to treat immediate sight-threatening CMV retinitis.[10] 
    • For the treatment of CMV pneumonia, ganciclovir is administered with immunoglobulin.
    • Other uses of ganciclovir include treatment of gastrointestinal disease in patients who have received transplants and in patients who are HIV positive.
    • Ganciclovir has also been used to treat CNS disease, including encephalitis and neuropathy, but with mixed results.
  • Valaciclovir:
    • Valaciclovir is licensed for prevention of CMV disease following renal transplantation.[10] 
  • Valganciclovir:[10] 
    • Is used for the initial treatment and maintenance treatment of CMV retinitis in AIDS patients.
    • It is also licensed for preventing CMV disease following solid organ transplantation from a CMV-positive donor.
  • Foscarnet:[10] 
    • Is active against CMV but is more toxic and therefore used as a second-line agent.
  • Cidofovir:[10] 
    • Is given in combination with probenecid for CMV retinitis in AIDS patients when ganciclovir and foscarnet are contra-indicated..

Management of congenital CMV infection

  • Ganciclovir may be used to treat neonates with symptoms at birth.
  • Congenitally infected infants, both symptomatic and asymptomatic at birth, require follow-up evaluation to detect sequelae.
  • Congenital CMV infection can be diagnosed at birth by detection of viral DNA by PCR in dried blood spots (Guthrie card) collected in the first days of life. However, screening for congenital CMV infection is not currently recommended in the UK.[11]
  • The prognosis of patients with CMV hepatitis is generally good. Most patients recover completely.
  • Symptoms can persist, usually in the form of fatigue, for several months after primary infection.
  • CMV pneumonia in patients who have received marrow transplants once carried a mortality rate higher than 85%. The use of ganciclovir plus high-dose immunoglobulin for the treatment of CMV pneumonia in patients who have received allogeneic marrow transplants has lowered the mortality rate to 30-60%.
  • Because patients who develop CMV disease are immunocompromised, their prognosis is determined by their underlying disease.
  • CMV has recently been implicated in the development of a variety of different cancers.[12]

Prophylaxis with antiviral medications reduces CMV disease and CMV-associated mortality in solid organ transplant recipients. They should be used routinely in CMV-positive recipients and in CMV-negative recipients of CMV-positive organ transplants.[13] 

  • Ganciclovir is used for the prevention of CMV disease during immunosuppressive therapy following organ transplantation.[10] 
  • Other drugs have been used for CMV prophylaxis, but none is as effective as ganciclovir.[2] 
  • Ganciclovir, aciclovir and valaciclovir have been used for prophylaxis and early treatment in patients who have received allogeneic marrow transplants.
  • Prophylactic antiviral treatment and intensive monitoring, followed by pre-emptive antiviral treatment, are both commonly used management strategies to reduce risk of CMV infection following renal transplantation.[14]
  • Aciclovir has also been used in patients who have received other types of transplants.

Further reading & references

  1. Boeckh M; Complications, diagnosis, management, and prevention of CMV infections: current and future. Hematology Am Soc Hematol Educ Program. 2011;2011:305-9.
  2. Akhter K; Cytomegalovirus, Medscape, Aug 2011
  3. Barrett L, Fowke KR, Grant MD; Cytomegalovirus, aging, and HIV: a perfect storm. AIDS Rev. 2012 Jul;14(3):159-67.
  4. Baroco AL, Oldfield EC; Gastrointestinal cytomegalovirus disease in the immunocompromised patient. Curr Gastroenterol Rep. 2008 Aug;10(4):409-16.
  5. Buonsenso D, Serranti D, Gargiullo L, et al; Congenital cytomegalovirus infection: current strategies and future perspectives. Eur Rev Med Pharmacol Sci. 2012 Jul;16(7):919-35.
  6. Plosa EJ, Esbenshade JC, Fuller MP, et al; Cytomegalovirus infection. Pediatr Rev. 2012 Apr;33(4):156-63; quiz 163.
  7. Transplantation guidelines (various), British Transplantation Society (various dates)
  8. Beam E, Razonable RR; Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment. Curr Infect Dis Rep. 2012 Dec;14(6):633-41. doi: 10.1007/s11908-012-0292-2.
  9. Alexopoulos SP, Lindberg L, Subramanyan RK, et al; Cytomegalovirus Prophylaxis in Solid Organ Transplantation. Curr Med Chem. 2012 Sep 3.
  10. British National Formulary; 64th Edition (Sep 2012) British Medical Association and Royal Pharmaceutical Society of Great Britain, London
  11. Cytomegalovirus, UK Screening Portal
  12. Johnsen JI, Baryawno N, Soderberg-Naucler C; Is human cytomegalovirus a target in cancer therapy? Oncotarget. 2011 Dec;2(12):1329-38.
  13. Hodson EM, Craig JC, Strippoli GF, et al; Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD003774.
  14. Legendre C, Beard SM, Crochard A, et al; The cost-effectiveness of prophylaxis with valaciclovir in the management of cytomegalovirus after renal transplantation. Eur J Health Econ. 2005 Mar 12;.

Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.

Original Author:
Dr Colin Tidy
Current Version:
Peer Reviewer:
Dr Helen Huins
Last Checked:
04/01/2013
Document ID:
2026 (v22)
© EMIS